BioExecutive Institute: Comparative Effectiveness: A Driver for Competitive Effectiveness

As Life Sciences companies gear up for comparative effectiveness implementation, many questions are coming up. Where does comparative effectiveness best fit in the organization? How will it really impact portfolio decisions? These topics and more will be addressed at the BioExec Institute 2010.

Listen to a preview of BioExec Institute 2010 presented by Deloitte on Comparative Effectiveness: A Driver for Competitive Effectiveness on August 17, 2010 at 2:00pm EST. The session will discuss:

How informatics can provide critical insights that have historically not been readily available.
Leveraging informatics to accelerate and improve the quality of decision making.
Competing in a marketplace that requires information transparency, clinical effectiveness in a real world environment, and appropriate economical value in use.
Learn about the various implications and multifaceted opportunities associated with comparative effectiveness implementation. The webcast is free, but registration required. Register.

About the BioExec Institute
Co-produced by UC Berkeley, Deloitte and Prescience Intl, the BioExec Institute brings together director and VP-level management for this six-day interactive program [3 modules of 2 days each] on Oct 7-8, Nov 4-5 and Dec. 7-8, 2010. Participants will have the opportunity to debate the strategies and tactics with key leaders who have provided unique value to the industry such as Mark Edwards, President, Deloitte Recap, LLC, Mervyn J. Turner, Ph.D., Chief Strategy Officer, Merck & Co. Inc. & Sr. Vice President, Emerging Markets, Merck Research Laboratories, Barbara Ryan, Managing Director, Deutsche Bank, Dennis Schmatz, PhD, President, Medicines for Malaria Venture NA; Chair - Expert Scientific Advisory Board (ESAC) Medicines for Malaria Venture, Board Member, Medicines for Malaria Venture, Scott Evangelista, Principal, National Commercial Practice Leader, Deloitte Consulting LLP, Martin Babler, President and CEO, Talima Therapeutics Inc, Dave Summa, Board of Directors, Sequoia Pharmaceuticals, Acumen Pharmaceuticals, and Agrivida, Inc., David Kessler, MD, JD, Best Selling Author and Former Commissioner of the US Food and Drug Administration (FDA), Keith Donnermeyer, Partner and National Life Sciences Sector Leader, Deloitte & Touche LLP, Abhay Joshi, PhD, President & CEO, Alvine Pharmaceuticals, and many others.

Space is limited to 60 participants. For more information or to register, visit http://www.prescienceintl.com/bioexec.html.